Please try another search
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Name | Age | Since | Title |
---|---|---|---|
Brian D. Barash | - | - | Member of Scientific Advisory Board |
Andrew J. Cutler | - | - | Member of Scientific Advisory Board |
John S. Markowitz | - | - | Member of Scientific Advisory Board |
Alice Mao | - | - | Member of Scientific Advisory Board |
Ann Childress | - | - | Member of Scientific Advisory Board |
Sharon B. Wigal | - | - | Member of Scientific Advisory Board |
Peter J. Werth | 84 | 2018 | Director |
Declan Quinn | - | - | Member of Scientific Advisory Board |
Ignacio Herman Valdes | - | - | Member of Scientific Advisory Board |
Dinohra Munoz-Silva | - | - | Member of Scientific Advisory Board |
Jeffrey S. Ervin | 46 | 2024 | Director |
Bryan Jay Lawrence | 58 | 2024 | Director |
Jeffrey Newcorn | - | - | Member of Scientific Advisory Board |
Laurence L. Greenhill | - | - | Member of Scientific Advisory Board |
John A. Roberts | 65 | 2024 | Independent Director |
Shane J. Schaffer | 49 | 2012 | CEO & Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review